With a presence in over 90 countries, ADVANZ PHARMA offers a diverse portfolio of more than 200 established, off-patent molecules, including orphan drugs. The company aims to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia, and collaborates with innovative biopharma and pharmaceutical development companies to bring medicines to patients. The product portfolio covers a broad range of therapeutic areas, and the company values entrepreneurship, speed, and integrity in achieving its ambition.